Correlating efficacy and immunogenicity in malaria vaccine trials

被引：22

作者：

McCall, Matthew B. B. ^{[1
,2
,3
]}

Kremsner, Peter G. ^{[1
,2
,3
]}

Mordmueller, Benjamin ^{[1
,2
,3
]}

机构：

[1] Univ Tubingen, Inst Tropenmed, Wilhelmstr 27, D-72074 Tubingen, Germany

[2] Deutsch Zentrum Infekt Forsch, Tubingen, Germany

[3] Ctr Rech Med Lambarene, Lambarene, Gabon

来源：

SEMINARS IN IMMUNOLOGY | 2018年 / 39卷 / 0C期

关键词：

Malaria; Vaccine; Substitute endpoint; Immunological correlate; Immunological surrogate; Controlled human malaria infection; PLASMODIUM-FALCIPARUM; CIRCUMSPOROZOITE PROTEIN; IMMUNE-RESPONSES; ACQUIRED-IMMUNITY; PFSPZ VACCINE; DOUBLE-BLIND; T-CELLS; ANTIBODY-RESPONSES; CLINICAL-TRIALS; GAMMA-GLOBULIN;

D O I：

10.1016/j.smim.2018.08.002

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The availability of an effective and appropriately implemented malaria vaccine would form a crucial cornerstone of public health efforts to fight this disease. Despite many decades of research, however, no malaria vaccine has yet shown satisfactory protective efficacy or been rolled-out. Validated immunological substitute endpoints have the potential to accelerate clinical vaccine development by reducing the required complexity, size, duration and cost of clinical trials. Besides facilitating clinical development of existing vaccine candidates, understanding immunological mechanisms of protection may drive the development of fundamentally new vaccination approaches. In this review we focus on correlates of protection in malaria vaccine development: Does immunogenicity predict malaria vaccine efficacy and why is this question particularly difficult? Have immunological correlates accelerated malaria vaccine development in the past and will they facilitate it in the future? Does Controlled Human Malaria Infection represent a valid model for identifying such immunological correlates, or a correlate of protection against naturally-acquired malaria in itself?

引用

页码：52 / 64

页数：13

共 50 条

[11] A tale of four studies: HIV vaccine immunogenicity and efficacy in clinical trials [J].

Zolla-Pazner, Susan ;

Michael, Nelson L. ;

Kim, Jerome H. .

LANCET HIV, 2021, 8 (07) :E449-E452

[12] Correlates of malaria vaccine efficacy [J].

Stanisic, Danielle I. ;

McCall, Matthew B. B. .

EXPERT REVIEW OF VACCINES, 2021, 20 (02) :143-161

[13] Steady progress toward a malaria vaccine [J].

Lyke, Kirsten E. .

CURRENT OPINION IN INFECTIOUS DISEASES, 2017, 30 (05) :463-470

[14] Improving the immunogenicity and protective efficacy of a whole-killed malaria blood-stage vaccine by chloroquine [J].

Fu, Yong ;

Lu, Xiao ;

Zhu, Feng ;

Zhao, Yunxiang ;

Ding, Yan ;

Ye, Lilin ;

Guo, Bo ;

Liu, Taiping ;

Xu, Wenyue .

PARASITE IMMUNOLOGY, 2020, 42 (01)

[15] Malaria vaccine trials in pregnant women: An imperative without precedent [J].

Healy, Sara A. ;

Fried, Michal ;

Richie, Thomas ;

Bok, Karin ;

Little, Maggie ;

August, Allison ;

Riley, Laura ;

Swamy, Geeta K. ;

Wylie, Blair J. ;

Menendez, Clara ;

Muehlenbachs, Atis ;

Doumbo, Ogobara ;

Greenwood, Brian ;

Billingsley, Peter F. ;

Hoffman, Stephen L. ;

Duffy, Patrick E. .

VACCINE, 2019, 37 (06) :763-770

[16] The past decade in malaria synthetic peptide vaccine clinical trials [J].

Nardin, Elizabeth .

HUMAN VACCINES, 2010, 6 (01) :27-38

[17] A phase I/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS,S/AS02A in malaria-naive adults [J].

Kester, Kent E. ;

McKinney, Denise A. ;

Tornieporth, Nadia ;

Ockenhouse, Christian F. ;

Heppner, D. Gray, Jr. ;

Hall, Ted ;

Wellde, Bruce T. ;

White, Kate ;

Sun, Peifang ;

Schwenk, Robert ;

Krzych, Urszula ;

Delchambre, Martine ;

Voss, Gerald ;

Dubois, Marie-Claude ;

Gasser, Robert A., Jr. ;

Dowler, Megan G. ;

O'Brien, Megan ;

Wittes, Janet ;

Wirtz, Robert ;

Cohen, Joe ;

Ballou, W. Ripley .

VACCINE, 2007, 25 (29) :5359-5366

[18] An expanding toolkit for preclinical pre-erythrocytic malaria vaccine development: bridging traditional mouse malaria models and human trials [J].

Steel, Ryan W. J. ;

Kappe, Stefan H. I. ;

Sack, Brandon K. .

FUTURE MICROBIOLOGY, 2016, 11 (12) :1563-1579

[19] Malaria vaccine development: Lessons from the field [J].

Todryk, Stephen ;

Bejon, Philip .

EUROPEAN JOURNAL OF IMMUNOLOGY, 2009, 39 (08) :2007-2010

[20] PATH Malaria Vaccine Initiative (MVI) Perspectives on the status of malaria vaccine development [J].

Birkett, Ashley J. .

HUMAN VACCINES, 2010, 6 (01) :139-145

← 1 2 3 4 5 →